Promega Developing OncoMate™ MSI Assay as Companion Diagnostic for Endometrial Cancer Drug Candidate from Incyte

Promega Corporation announced today its intent to develop the Promega OncoMate microsatellite instability (MSI) Assay as a companion diagnostic test for retifanlimab, Incytes anti-PD-1 drug candidate, in endometrial cancer.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, September 22, 2020
Information
Tags: 
Stem cells, Biotechnology, Pharmaceutical, Oncology, Health, Medical devices, Genetics, Clinical trials, Branches of biology, Natural sciences, Promega, Microsatellite instability, Biology, MSI, Microsatellite, Assay
Geotags: 
United States, South America, CENTRAL AMERICA, Europe, Wisconsin
⚠ generated by AI ↴
Organisation: 
PROMEGA CORPORATION
Summary
Key Points: 
  • Promega Corporation announced today its intent to develop the Promega OncoMate microsatellite instability (MSI) Assay as a companion diagnostic test for retifanlimab, Incytes anti-PD-1 drug candidate, in endometrial cancer.
  • Promega and Incyte intend to work together in the future to develop the Promega OncoMate MSI Assay as a companion diagnostic in other markets.
  • The OncoMate MSI Assay received CE marking in Europe earlier this year.
  • Promega intends to seek regulatory clearance for OncoMate MSI in the United States and China.


Promega Corporation announced today its intent to develop the Promega OncoMate™ microsatellite instability (MSI) Assay as a companion diagnostic test for retifanlimab, Incyte’s anti-PD-1 drug candidate, in endometrial cancer. Financial terms of the global agreement with Incyte were not disclosed.

Microsatellite instability-high (MSI-H) is a key feature of Lynch syndrome tumors, indicative of a germline mutation in mismatch repair genes, but can also arise sporadically. It occurs frequently in endometrial cancer. The importance of the MSI-H biomarker has been further emphasized since the 2015 finding that MSI-H tumors have a prolonged and durable response to PD-1 inhibitors.

“This announcement further underscores Promega’s dedication to advance the promise of MSI technology globally, building on over 20 years of expertise in this field,” said Heather Tomlinson, Director of Clinical Diagnostics at Promega Corporation.

Promega and Incyte intend to work together in the future to develop the Promega OncoMate MSI Assay as a companion diagnostic in other markets.

The OncoMate™ MSI Assay received CE marking in Europe earlier this year. Promega MSI technology is one of the leading standard tests for MSI status detection in research laboratories and achieved innovation status and priority review by the National Medical Products Administration (NMPA) in China. It has been used extensively in clinical research for more than 15 years and is supported by more than 140 peer-reviewed publications. Promega intends to seek regulatory clearance for OncoMate™ MSI in the United States and China.

To learn more about Promega MSI testing, visit: www.promega.com/MSI

About Promega Corporation

Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. Our product portfolio of over 4,000 products support a range of life science work across areas such as cell biology; DNA, RNA and protein analysis; drug development; human identification and molecular diagnostics. For over 40 years these tools and technologies have grown in their application and are used today by scientists and technicians in labs for academic and government research, forensics, pharmaceuticals, clinical diagnostics and agricultural and environmental testing. Promega is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors. For more information, visit www.promega.com.

Copyright: 
Copyright Business Wire 2020